Stockscreener 앱 받기
1.21
0.83%
0.01
전일 마감가:
$1.20
열려 있는:
$1.2
하루 거래량:
50,908
Relative Volume:
0.33
시가총액:
$59.64M
수익:
$42,000
순이익/손실:
$-12.38M
주가수익비율:
-4.5938
EPS:
-0.2634
순현금흐름:
$-9.61M
1주 성능:
+4.31%
1개월 성능:
-1.63%
6개월 성능:
-37.63%
1년 성능:
-39.20%
1일 변동 폭
$1.1686
$1.22
1주일 범위
$1.15
$1.25
52주 변동 폭
$0.91
$3.22
Entera Bio Ltd Stock (ENTX) Company Profile
명칭
Entera Bio Ltd
전화
972-2-532-7151
주소
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
1.21 | 59.64M | 42,000 | -12.38M | -9.61M | -0.2634 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-22 | 개시 | Aegis Capital | Buy |
Entera Bio Ltd 주식(ENTX)의 최신 뉴스
Entera Bio Ltd (ENTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Entera Bio Ltd (ENTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Entera Bio Ltd (ENTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
After Novo Nordisk's Oral Peptide Playbook Made History – Could Entera be The Next Big Peptide Story? - Benzinga
Entera Bio Ltd (ENTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
ENTX SEC FilingsEntera Bio Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Entera Bio Ltd (ENTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Entera Bio Ltd (ENTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Entera Bio Ltd (ENTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Entera Bio Ltd (ENTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Entera Bio Ltd (ENTX) Institutional Confidence - TradingKey
Entera Bio reports preclinical data for two oral peptide programs By Investing.com - Investing.com South Africa
Entera Bio reports preclinical data for two oral peptide programs - Investing.com UK
Entera Reports Robust Preclinical Data for EB612 (Oral - GlobeNewswire
Experimental oral hormone pills aim at hypoparathyroidism, obesity - Stock Titan
Entera Bio Ltd. (ENTX) Presents at Endocrine Society's Annual Meeting (ENDO 2026)Slideshow - Seeking Alpha
Entera Bio presents Phase 1 data on single-tablet EB613 - Investing.com
Daily oral tablet EB613 shows comparable results to Forteo - Stock Titan
Entera Bio (ENTX) Q1 2026 Earnings: Narrowed Loss Beats Estimates as Pipeline AdvancesMargin Expansion Trends - newsline.com
Entera Bio (ENTX) Slides 4.1% as Selling Pressure Tests Key Support at $1.11Long Term Entry Picks - newsline.com
ENTX Q1 2026 Earnings: Surprise EPS Beat as Operating Loss NarrowsEarnings Beat Alert - newsline.com
ENTX | Entera Bio Ltd. Ordinary Executive Compensation - Quiver Quantitative
Entera Bio (ENTX) Holds Steady at $1.22 as Stock Consolidates Near SupportElliott Wave Count - newsline.com
[ARS] Entera Bio Ltd. SEC Filing - Stock Titan
Entera Bio (NASDAQ: ENTX) 2026 proxy seeks board, equity plan and share capital approvals - Stock Titan
Entera Bio Is Building the Future of Peptides Beyond the Needle (NASDAQ: ENTX) - TipRanks
ENTX Q1 2026 Earnings: Better-than-Expected Losses Reflect Clinical ProgressAdjusted Earnings Analysis - The Legal Advocate
Entera Bio presents clinical data on osteoporosis candidate By Investing.com - Investing.com Nigeria
Entera Bio presents clinical data on osteoporosis candidate - Investing.com
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for OsteoporosisSingle Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation - The Manila Times
Experimental osteoporosis pill gets late-breaking ENDO 2026 slot - Stock Titan
ENTX Q1 2026 Earnings: Narrower-than-Expected Loss Reflects Cost Discipline Amid Pre-Revenue StageROA Comparison - newsline.com
ENTX - Finviz
Entera Bio Ltd. (ENTX) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Strong Earnings BeatRevenue Estimate Trend - Newser
Entera Bio (ENTX) Q1 2026 Earnings: Narrowing Losses as Cash Burn Remains in FocusEarnings Revision Report - The Legal Advocate
Entera Bio (ENTX) Faces Selling Pressure as Stock Dips Below Key ResistancePrice Action Signals - newser.com
[EFFECT] Entera Bio Ltd. SEC Filing - Stock Titan
Entera Bio (NASDAQ: ENTX) registers 19.6M shares; $14.5M possible on warrant exercises - Stock Titan
Entera Bio Ltd.Ordinary Shares (NQ: ENTX - FinancialContent
Entera Bio (ENTX) shareholder vote set for July 14, 2026; 2.5M-share plan increase - Stock Titan
TradingKey - TradingKey
Number of shareholders of Entera Bio Ltd. – HAM:5DT - TradingView
MSN Money - MSN
Entera Bio Sees Funding Sufficient Through 1Q27 >ENTX - Moomoo
Entera Bio Highlights Q1 2026 Progress and Financing - TipRanks
Entera Bio (ENTX) grants COO 72,993 RSUs in lieu of cash bonus - Stock Titan
Entera Bio (ENTX) CFO receives 58,394 RSUs through A2Z Counseling Ltd. - Stock Titan
Entera Bio (ENTX) awards 87,591 RSUs to Chief of R&D Burshtein - Stock Titan
Entera Bio Ltd. (NASDAQ: ENTX) registers 19.6M shares for resale under S-3 - Stock Titan
Entera Bio Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Entera Bio (ENTX) widens Q1 loss as R&D doubles and cash runway nears Q1 2027 - Stock Titan
Entera Bio Ltd (ENTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):